Larimar Therapeutics
LRMR3.6305.22% ( -0.200 )
Larimar Therapeutics (LRMR)
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide...
- Open
- 3.810
- High
- 3.895
- Low
- 3.615
- Prev. Close
- 3.830
- Volume
- 1.80M
- Turnover
- 6.60M
- Avg Price
- 3.679
- Bid/Ask Ratio
- --
- Amplitude
- 7.31%
- 52wk High
- 6.420
- Volume Ratio
- 1.51
- Turnover Ratio
- 2.99%
Larimar Therapeutics Analyst Rating
View MoreForecast & Rating
Jul 21, 2026Price forecast
$14.40296.69%
Forecast & RatingStrong buy
11analysts
- Strong buy81.82%
- Buy18.18%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- PUBT · Jul 8 at 03:06 PM
Larimar Therapeutics director Thomas Edward Hamilton acquires USD 166,890 of common shares
- prnewswire · Jul 1 at 07:15 PM
20:11 ETINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR
- Tip Ranks · Jun 29 at 11:15 AM
Nomlabofusp Progress and Durable Efficacy Support Buy Rating on LRMR with Unchanged $25 Price Target
- Quartr · Jun 29 at 09:24 AM
LRMR: Nomlabofusp shows sustained efficacy and safety in FA, with BLA submission and phase III underway
- benzinga_article · Jun 29 at 09:15 AM
Larimar Stock Slides 15% Despite FDA Backing Rolling Submission For Rare Disease Drug
- benzinga_article · Jun 29 at 07:11 AM
Biohaven, Goodyear Tire And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
